Navigation Links
Pharsight Hosts Fourth Annual PKS User Group Meeting
Date:9/28/2007

the FDA's regulation 21 CFR Part 11, which has set new standards for computer system validation and usage. PKS is directly integrated with WinNonlin(R) Enterprise(TM), Pharsight's industry-leading PK/PD modeling and analysis tool for state-of-the-art modeling and analyses, and supports direct access to any ODBC-capable data source. PKS also supports analysis with leading tools such as NONMEM(R) and SAS(R), and data import from leading clinical data management and laboratory information management systems such as Watson LIMS(TM). PKS software is designed to complement other Pharsight products, including Trial Simulator(TM) and Drug Model Explorer(R) (DMX(R)), which are used for computer-based drug-disease modeling, clinical trial simulation, and drug model visualization.

About Pharsight Corporation

Pharsight Corporation develops and markets integrated products and services that enable pharmaceutical and biotechnology companies to achieve significant and enduring improvements in the development and use of therapeutic products. The company's goal is to help customers reduce the time, cost and risk of drug development, as well as optimize the post-approval marketing and use of pharmaceutical products.

Pharsight's approach enhances the fundamental element of drug development success: strong decision-making. By adopting the Pharsight approach, customers acquire a new decision-making process with the potential to systematically improve every level and phase of their business and scientific processes. Pharsight is headquartered in Mountain View, California. Information about Pharsight is available at http://www.pharsight.com.

Registered Trademarks and Trademarks

Pharsight, Pharsight Knowledgebase Server (PKS), WinNonlin Enterprise, Trial Simulator and Drug Model Explorer (DMX), are trademarks or registered trademarks of Pharsight Corporation. All other brand and product names are trademarks o
'/>"/>

SOURCE Pharsight Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Bacterial RNA Isolation From Infected Eukaryotic Hosts
2. Bacterial RNA Isolation From Infected Eukaryotic Hosts
3. High Tech Happy Hour will mark fourth anniversary
4. Niceware releases fourth version of labeling software
5. Wisconsin-based Third Wave reports increased revenue for 2003, fourth quarter
6. NameProtect releases annual list of top trademarkers
7. Doyle says new contracts saving state more than $16 million annually
8. Department of Commerce offers up to $1 million annually to aid tech entrepreneurs
9. Annual Bioethics Forum to explore genetic testing
10. Annual Conference Honors Tech Grant Winners
11. Cardinal Health likes growth potential of Viasys NeuroCare Group
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... York (PRWEB) December 23, 2014 According to ... Long Island Affiliate of ITRA Global, the national office market ... steady recovery. This is evidenced by the third quarter’s ... stock market. Low energy costs have held inflation down ... only negative is the housing market remaining soft. , This ...
(Date:12/24/2014)... The report expects global cell isolation and ... also provides a carefully analyzed data about the vital ... market. , Full Copy of Report @ http://bit.ly/1yUxy0T ... for cell expansion will keep witnessing growth at an ... to be driven by rapid technological advancements, government funding ...
(Date:12/24/2014)... , Dec. 23, 2014 Vermillion, Inc. ... on gynecologic disease, announced today that investors including ... Birchview Fund LLC and several Vermillion directors have ... shares of Vermillion,s common stock and warrants to ... a private placement.  Under the ...
(Date:12/24/2014)... Dec. 23, 2014  Rock Creek Pharmaceuticals, Inc., (NASDAQ: ... filed a Clinical Trial Application (CTA) with the ... Agency (MHRA) seeking regulatory approval to initiate clinical trials ... Citrate. Contingent on the Company receiving CTA ... I trial to assess the safety, tolerability and dose ...
Breaking Biology Technology:ITRA Global Reports Long Island Is Out of Sync With The National Office Market 2ITRA Global Reports Long Island Is Out of Sync With The National Office Market 3The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 2The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 4Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 5Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3
... Primary ... SAN DIEGO, May 27 Favrille, Inc. (Nasdaq:,FVRL) ... trial,of Specifid(TM) following Rituxan(R) in patients with follicular B-cell,non-Hodgkin,s ... Analysis of time to progression (TTP), the primary endpoint ...
... May 26 /Xinhua-PRNewswire/ -- WuXi PharmaTech (NYSE:,WX), ... research,and development outsourcing company with operations in ... that it has appointed Dr. Peng Wang ... http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO ), Prior to ...
... SAN DIEGO, May 23 Amylin Pharmaceuticals,Inc. (Nasdaq: ... Stockholders on,Friday, May 30, 2008 at 11:00 a.m. PT ... the Annual Meeting, Daniel M.,Bradbury, President and Chief Executive ... The live presentation will be Web cast, and ...
Cached Biology Technology:Favrille Announces Results from Phase 3 Registration Trial of Specifid in Patients with Follicular B-Cell Non-Hodgkin's Lymphoma 2Favrille Announces Results from Phase 3 Registration Trial of Specifid in Patients with Follicular B-Cell Non-Hodgkin's Lymphoma 3WuXi PharmaTech (NYSE: WX) Appoints Dr. Peng Wang as VP of Discovery Biology 2
(Date:12/10/2014)... December 9, 2014   ... Platform   Jifflenow, ... scheduling solutions for business-to-business (B2B) events, today announced ... in mobile near-field communication (NFC), Bluetooth low energy ... (Logo: http://photos.prnewswire.com/prnh/20140612/691055) , Jifflenow will integrate ...
(Date:12/4/2014)... , Dec. 3, 2014  Crossmatch™, a ... announced that its DigitalPersona ® Pro Enterprise ... have been deployed throughout First Bank branch locations ... South Carolina and Virginia. First Bank, ... Southern Pines, North Carolina , selected ...
(Date:11/21/2014)... November 18, 2014 According to ... by Systems (Video, RFID, Access Control, Intrusion Detection, Parking ... Banks, Government), Component Service Geography - Global Forecasts to ... is projected to be around $25 Billion in 2014 ... growing at a CAGR of 8.69%. Browse ...
Breaking Biology News(10 mins):Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3
... with fossils led to Natural Sciences and Engineering Research Council ... the oldest known reptile that stands on two legs. ... years of research excellence by joining the ranks of the ... will induct him as a fellow during its annual conference, ...
... pinpointed a natural ingredient of human blood that effectively ... from infecting immune cells and multiplying. The virus blocker ... to full-blown AIDS and—because it works in a different ... of another class of drugs in the fight against ...
... the influenza virus that killed 50 million people in 1918, ... to how the virus killed so quickly and efficiently. , ... a team led by University of Wisconsin-Madison virologist Yoshihiro Kawaoka ... influenza strain - unleashes an immune response that destroys the ...
Cached Biology News:Old dinosaur research leads to new honor 2Discovery of an HIV inhibitor in human blood points to new drug class 2Discovery of an HIV inhibitor in human blood points to new drug class 3Study uncovers a lethal secret of 1918 influenza virus 2Study uncovers a lethal secret of 1918 influenza virus 3
...
Chicken polyclonal to UCK2 ( Abpromise for all tested applications). Antigen: Full length protein, corresponding to amino acids 1-261 of Human UCK2 Entrez Gene ID: 7371 Swiss Protein ID: ...
... a highly purified preparation of the catalytic ... which recognizes the identical cleavage site as ... enzymatic activity. Novagen&'s enzyme is produced in ... yield the highest activity available, and is ...
Physical Form: powder Color: white Removes FLAG peptide from N-terminal and Met-N-terminal fusion proteins. Supplied with optimized enterokinase buffer....
Biology Products: